Table 3.
Patients` characteristics
| Patient no. | Age at treatment (years) | Diagnosis | Additional risk-factors | Prior radiation treatment | Body length in treatment position (cm) |
|---|---|---|---|---|---|
|
1 |
8 |
ALL |
BCR-ABL+ |
/ |
154 |
|
2 |
4 |
ALL |
BCR-ABL+ |
/ |
110 |
|
3 |
18 |
ALL |
Non-response day 28 of induction therapy |
/ |
180 |
|
4 |
22 |
AML in CML |
M-BCR-ABL+ |
/ |
180 |
|
5 |
18 |
ALL Recurrence |
/ |
/ |
172 |
|
6 |
7 |
ALL Recurrence |
Biphenotypic leukemia |
/ |
130 |
|
7 |
13 |
ALL 2nd Recurrence |
/ |
12 Gy Whole Brain; 24 Gy Scrotum |
164 |
|
8 |
14 |
ALL Recurrence |
/ |
/ |
172 |
|
9 |
9 |
ALL Recurrence |
/ |
12 Gy Whole Brain |
158 |
| 10 | 12 | ALL Recurrence | / | 18 Gy Whole Brain | 152 |
Patient age ranged from 4–22 years. Most of the patients presented with ALL (acute lymphoblastic leukemia) in first or second remission, one patient presented with an acute blast crisis (AML: acute myeloic leukemia) in a CML (chronic myeloic leukemia) Risk factors such as positivity for the bcr-abl gene fusion product were seen in some case, two patients had had prior radiation therapy. Body length in treatment position (supine, feet outstretched) ranged from 110–180 cm.